Tirzepatide

Tirzepatide CAS No. 2023788-19-2
Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 to lower blood glucose levels.
Tirzepatide (Mounjaro) is a novel medication indicated as an adjunct to diet and exercise in the treatment of patients with type 2 diabetes mellitus. Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to lower blood glucose levels.

Mobile / Wechat：  13613621816（微信同号）

QQ: 2030459456

Related Products 

Company Profile 

   Founded in 2011, Harbin Jixianglong Biotech Co., Ltd. is a is a professional high-tech company specializing in R&D and production of polypeptide pharmaceuticals. Our advanced industry chain occupied in R&D, approbation and industrialization of peptides API and preparation.
   Jixianglong has peptide drug production workshop and pilot workshop for personalized cancer neoantigen peptide vaccine which approved by GMP standard. More than 300 sets advanced instruments for production and testing, such as Solid phase synthesizer, Preparative liquid chromatograph, Freeze dryer, High performance liquid chromatograph etc.
Main Products:
10 items completed polypeptide API declared:
Eptifibatide, Somatostatin, Terlipressin Acetate, Thymalfasin, Atosiban Acetate, Carbetocin, Oxytocin, Ganirelix Acetate, Octreotide Acetate, Cetrorelix Acetate.
N items as researching reserve series:
Teriparatide, Bivalirudin, Liraglutide, Nesiritide, Abaloparatide, Semaglutide, Personalized cancer neoantigen peptide vaccine,  Peptide drug conjugate (PDC).